ArticleACS omega2024
A Multibranch Neural Network for Drug-Target Affinity Prediction Using Similarity Information.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- GSF-DTA: An Innovative Graph-Sequence Fusion Framework for Drug-Target Affinity Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Sequence-based prediction of drug-target binding using machine learning, deep learning and ensemble models without 3D structural information.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predicting drug-target affinity (DTA) is beneficial for accelerating drug discovery. In recent years, graph structure-based deep learning models have garnered significant attention in this field. However, these models typically handle drug or target protein in isolation and only extract the molecular structure information on the drug or protein itself. To address this limitation, existing network-based models represent drug-target interactions or affinities as a knowledge graph to capture the interaction information. In this study, we propose a novel solution. Specifically, we introduce drug similarity information and protein similarity information into the field of DTA prediction. Moreover, we propose a network framework that autonomously extracts similarity information, avoiding reliance on knowledge graphs. Based on this framework, we design a multibranch neural network called GASI-DTA. This network integrates similarity information, sequence information, and molecular structure information. Comprehensive experimental results conducted on two benchmark data sets and three cold-start scenarios demonstrate that our model outperforms state-of-the-art graph structure-based methods in nearly all metrics. Furthermore, it exhibits significant advantages over existing network-based models, outperforming the best of them in the majority of metrics. Our study's code and data are openly accessible at http://github.com/XiaoLin-Yang-S/GASI-DTA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.